By Ann Palma —

About
Court Report Supplement:  Periodically, we will
report on biotech and pharma cases that were inadvertently omitted from
our Court Report column.

Tawnsaura
Group, LLC v. Direct Digital, LLC
8:13-cv-00004;
filed January 2, 2013 in the Central District of California

Infringement
of U.S. Patent Nos. 5,874,471 ("Orthomolecular medical use of L-Citrulline for
vasoprotection, relaxative smooth muscle tone and cell protection," issued
February 23, 1999) and 6,028,107 (same title, February 22, 2000) based on
Defendant's manufacture, use, offers for sale, and sales of nutritional
supplements containing L-Citrulline and/or L-Citrulline Malate used to boost
testosterone levels, including Defendant's Nugenix products.  View the complaint here.

Tawnsaura
Group, LLC v. M.D. Science Lab, LLC
8:13-cv-00051;
filed January 11, 2013 in the Central District of California

Infringement
of U.S. Patent Nos. 5,874,471 ("Orthomolecular medical use of L-Citrulline for
vasoprotection, relaxative smooth muscle tone and cell protection," issued
February 23, 1999) and 6,028,107 (same title, February 22, 2000) based on
Defendant's manufacture, use, offers for sale, and sales of nutritional
supplements containing L-Citrulline and/or L-Citrulline Malate used to activate
the nitric oxide pathways for vasodilation, including Defendant's "Herbal Viva
Super Sex Booster" product.  View the complaint here.

Tawnsaura
Group, LLC v. Tribravus Enterprises, LLC (d/b/a iForce Nutrition)
8:13-cv-00080;
filed January 16, 2013 in the Central District of California

Infringement
of U.S. Patent Nos. 5,874,471 ("Orthomolecular medical use of L-Citrulline for
vasoprotection, relaxative smooth muscle tone and cell protection," issued
February 23, 1999) and 6,028,107 (same title, February 22, 2000) based on Defendant's
manufacture, use, offers for sale, and sales of nutritional supplements
containing L-Citrulline and/or L-Citrulline Malate used to increase the plasma
concentration of arginine, including Defendant's "Hemavol"-branded
products.  View the complaint here.

Tawnsaura
Group, LLC v. Muscle Warfare, Inc.
8:13-cv-00143;
filed January 29, 2013 in the Central District of California

Infringement
of U.S. Patent Nos. 5,874,471 ("Orthomolecular medical use of L-Citrulline for
vasoprotection, relaxative smooth muscle tone and cell protection," issued
February 23, 1999) and 6,028,107 (same title, February 22, 2000) based on
Defendant's manufacture, use, offers for sale, and sales of nutritional
supplements containing L-Citrulline and/or L-Citrulline Malate used to increase
the plasma concentration of arginine, including Defendant's "Napalm"-branded
products.  View the complaint here.

Massachusetts
Institute of Technology, et al. v. Shire PLC, et al.
1:13-cv-10020;
filed January 4, 2013 in the District of Massachusetts

• Plaintiffs: 
Massachusetts Institute of Technology; Children's Medical Center Corp.
• Defendants: 
Shire PLC; Shire Pharmaceuticals, Inc.; Shire Regenerative Medicine, Inc.

Infringement
of U.S. Patent Nos. 5,759,830 ("Three-dimensional fibrous scaffold
containing attached cells for producing vascularized tissue in vivo,"
issued June 2, 1998), 5,770,417 (same title, June 23, 1998), and 5,770,193 ("Preparation
of three-dimensional fibrous scaffold for attaching cells to produce
vascularized tissue in vivo," June 23, 1998) based on Defendants'
manufacture, marketing, and sales of products for a human fibroblast-derived
dermal substitute indicated for use in treatment of full-thickness diabetic
foot ulcers, including Defendants' Dermagraft. 
View the complaint here.

Biologix
Research Company, LLC v. Max Scientific, LLC
1:13-cv-2021;
filed March 26, 2012 in the District of Delaware

Suit
brought against Defendant for alleged breach of contract, fraud and misrepresentation,
and conversion, among others, based on the Defendant's infringement of the
rights and interests of Biologix Research Company, LLC concerning U.S. Patent
No. 6,946,258 ("Rapid, immunochemical process for measuring thiopurine methyltransferase,"
September 20, 2005) and the sale of products containing at least Thiopurine Methyltransferase
(TPMT) — TPMT-1501-08 (8-patient TPMT kit); the TMPT-1501-24 (24- patient TPMT
kit); and the TPMT-1501-40 (40-patient TPMT kit). View the complaint here.